U.S. declares armed conflict with drug cartels, designating them as terrorist organizations and unlawful combatants, sparking legal and diplomatic disputes.
TG Therapeutics' positive trial data boosts shares, but risks remain from payer pressures and single-product reliance.
Applied Materials warns of a $710 million hit from new export rules, adding to headwinds for chip-equipment makers.
U.S. declares armed conflict with drug cartels, designating them as terrorist organizations and unlawful combatants, sparking legal and diplomatic disputes.
TG Therapeutics' positive trial data boosts shares, but risks remain from payer pressures and single-product reliance.
Applied Materials warns of a $710 million hit from new export rules, adding to headwinds for chip-equipment makers.